Clinical meaning of genetic polymorpism of CYP 2C9 in development of NSAIDs-gastropathy and gastrointestinal bleeding

15 березня 2017
830
Спеціальності :
Резюме

The results of investigation the features of genotype СУР 2С9 in patients with NSAIDs-induced gastrointestinal bleeding are presented in the article. In conclusion, genotypes CYP 2C9*1/*3 and CYP 2C9*1/*2 are associated with high risk of gastrointestinal bleeding, whereas the presence of the genotype CYP 2C9*2/*3 is not significantly associated with this risk. CYP 2C9 genotyping may be useful in identifying the subgroup of patients with potentially higher risk of gastroduodenal blee­ding when treated with NSAIDs metabolized by CYP 2C9. Further studies involving more patients to evaluate the effectiveness of CYP 2C9 genoty­ping in NSAID users are needed before this method will be introduced into clinical practice.